These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 17266386)

  • 1. Which physicians are affected most by Medicaid preferred drug lists for statins and antihypertensives?
    Ketcham JD; Epstein AJ
    Pharmacoeconomics; 2006; 24 Suppl 3():27-40. PubMed ID: 17266386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medicaid preferred drug lists' costs to physicians.
    Ketcham JD; Epstein AJ
    Med Care; 2008 Jan; 46(1):9-16. PubMed ID: 18162850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of medicaid access restrictions on statin utilisation for patients treated by physicians practising in poor and minority neighbourhoods.
    Headen AE; Masia NA; Axelsen KJ
    Pharmacoeconomics; 2006; 24 Suppl 3():41-53. PubMed ID: 17266387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preferred drug lists and Medicaid prescriptions.
    Abdelgawad T; Egbuonu-Davis L
    Pharmacoeconomics; 2006; 24 Suppl 3():55-63. PubMed ID: 17266388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physicians' prescribing responses to a restricted formulary: the impact of Medicaid preferred drug lists in Illinois and Louisiana.
    Virabhak S; Shinogle JA
    Am J Manag Care; 2005 Jan; 11 Spec No():SP14-20. PubMed ID: 15700905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacist and physician satisfaction and rates of switching to preferred medications associated with an instant prior authorization program for proton pump inhibitors in the North Carolina Medicaid program.
    Jacobson Vann JC; Christofferson S; Humble CG; Wegner SE; Feaganes JR; Trygstad TK
    J Manag Care Pharm; 2010 May; 16(4):250-63. PubMed ID: 20433216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preferred drug lists: potential impact on healthcare economics.
    Ovsag K; Hydery S; Mousa SA
    Vasc Health Risk Manag; 2008; 4(2):403-13. PubMed ID: 18561515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts.
    Yeh JS; Franklin JM; Avorn J; Landon J; Kesselheim AS
    JAMA Intern Med; 2016 Jun; 176(6):763-8. PubMed ID: 27159336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How similar are states' Medicaid preferred drug lists?
    Ketcham JD; Ngai JK
    Am J Manag Care; 2008 Nov; 14(11 Suppl):SP46-52. PubMed ID: 18991481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Medicaid preferred drug lists on therapeutic adherence.
    Ridley DB; Axelsen KJ
    Pharmacoeconomics; 2006; 24 Suppl 3():65-78. PubMed ID: 17266389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Personal Formularies of Primary Care Physicians Across 4 Health Care Systems.
    Galanter W; Eguale T; Gellad W; Lambert B; Mirica M; Cashy J; Salazar A; Volk LA; Falck S; Shilka J; Van Dril E; Jarrett J; Zulueta J; Fiskio J; Orav J; Norwich D; Bennett S; Seger D; Wright A; Linder JA; Schiff G
    JAMA Netw Open; 2021 Jul; 4(7):e2117038. PubMed ID: 34264328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changing prescribing patterns and increasing prescription expenditures in Medicaid.
    Fink KS; Byrns PJ
    Ann Fam Med; 2004; 2(5):488-93. PubMed ID: 15506586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient, Physician and Organizational Influences on Variation in Antipsychotic Prescribing Behavior.
    Tang Y; Chang CC; Lave JR; Gellad WF; Huskamp HA; Donohue JM
    J Ment Health Policy Econ; 2016 Mar; 19(1):45-59. PubMed ID: 27084793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the potential link between Medicaid access restrictions, physician location, and health disparities.
    Headen A; Masia N
    Am J Manag Care; 2005 Jan; 11 Spec No():SP21-6. PubMed ID: 15700906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns and predictors of physician adoption of new cardiovascular drugs.
    Anderson TS; Lo-Ciganic WH; Gellad WF; Zhang R; Huskamp HA; Choudhry NK; Chang CH; Richards-Shubik S; Guclu H; Jones B; Donohue JM
    Healthc (Amst); 2018 Mar; 6(1):33-40. PubMed ID: 29066168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of statins by medicare beneficiaries post myocardial infarction: poor physician quality or patient-centered care?
    Schroeder MC; Robinson JG; Chapman CG; Brooks JM
    Inquiry; 2015; 52():. PubMed ID: 25724749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spillover effects of restrictive drug formularies in the statin class: a descriptive study of the Medicaid preferred drug list in Texas.
    Wang YR
    Manag Care Interface; 2006 Nov; 19(11):32-4. PubMed ID: 17137239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of two Medicaid prior-authorization policies on antihypertensive use and costs among Michigan and Indiana residents dually enrolled in Medicaid and Medicare: results of a longitudinal, population-based study.
    Law MR; Lu CY; Soumerai SB; Graves AJ; LeCates RF; Zhang F; Ross-Degnan D; Adams AS
    Clin Ther; 2010 Apr; 32(4):729-41; discussion 716. PubMed ID: 20435243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How many "Me-Too" drugs are enough? The case of physician preferences for specific statins.
    Austin PC; Mamdani MM; Juurlink DN
    Ann Pharmacother; 2006 Jun; 40(6):1047-51. PubMed ID: 16705028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medicaid prescription drug access restrictions: exploring the effect on patient persistence with hypertension medications.
    Wilson J; Axelsen K; Tang S
    Am J Manag Care; 2005 Jan; 11 Spec No():SP27-34. PubMed ID: 15700907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.